Amador Bioscience

Executive Summary

Amador Bioscience is a global contract research organization (CRO) founded in 2017, headquartered in Pleasanton, California, with operations spanning the US, China, and Europe. The company offers integrated drug development services from preclinical research through Phase IV clinical studies, specializing in translational science, clinical pharmacology, bioanalysis and biomarkers, and regulatory submission support. Its focus on AI/machine learning and drug delivery positions it uniquely to accelerate drug development timelines and improve success rates for biopharma clients. Amador serves a diverse client base ranging from emerging biotechs to established pharmaceutical companies, leveraging its global footprint to provide cost-effective, high-quality solutions across different regulatory environments.

Upcoming Catalysts (preview)

• Q3 2026Expansion of AI/ML-Enabled Bioanalytical Platform70% success
• Q4 2026Strategic Partnership with a Major Pharma for Drug Delivery Solutions55% success
• TBDNew Laboratory Facility in Europe to Enhance Regional Presence80% success